Use of percutaneous electrostimulation in the sacral region in the treatment of children with urinary tract symptoms associated with functional constipation

INTERVENTION: Behavioural It is a randomized, blinded clinical trial. Children will be allocated to one of the two groups by means of a randomization using opaque and sealed envelopes with sequential numbering obtained by computer generated random numbers. Patients in Group A (test) will undergo transassayed parassacral electrostimulation (TENS) three times a week, for a total of 20 sessions. Group B will undergo scapular electrostimulation (SHAM) three times a week for a total of 20 sessions. Patients who present typical UTI symptoms confirmed by uroculture after the start of the sessions will be removed and submitted to antibiotic therapy, returning to the study after absence of symptoms and confirmed sterile urine in a new uroculture. All patients will receive behavioral guidance consisting of urinal and bowel orientations such as going to the toilet after the three main meals for a period of 10 minutes; correct posture to the toilet with the trunk slightly flexed at the time of urination and / or defecation, using, when necessary, a reducer in the toilet and a foot support to facilitate abdominal press movement; avoiding coffee, tea, soda, chocolate and citrus fruits during treatment; urinate before bed; ingest more fluid during the day; not to retain urine when urinating, to eat high‐fiber foods. Surface Electrodes: A square, symmetrical biphasic current with a frequency of 10 Hz, a pulse width of 700 Hz will be used and the intensity increased to the level just below the motor threshold. Electrical stimulation will be performed three times a week, every other day, with 20‐minute sessions lasting a total of 20 sessions. To measure the patient's perception of the group in which he or she believes to be allocated, a questionnaire will be applied after treatment to justify their choice. The research will be blind to the parents, the children and the evaluator in the post‐treatment. T3: After the sessions, patients will be advised to return to medical appointments at t Other Transcutaneous Electric Nerve Stimulation CONDITION: Constipation N00‐N99 Other bladder disorders; Constipation ; Constipation ; Other disorders of bladder Other disorders of bladder PRIMARY OUTCOME: Improvement of urinary symptoms measured by the Toronto score (score less than 6 for boys and less than 9 for girls), clinical improvement of constipation measured by the frequency of exits (more than 3 exits per week) and less than 02 criteria of Rome IV, complete bowel movement defined as complete evacuation sensation (more than 3 per week). SECONDARY OUTCOME: Improvement in symptoms associated with constipation: pain ; abdominal, stool strength, abdominal distention and stool consistency, improvement of fecal incontinence, ; (Urofluxometry, bladder capacity, post‐voiding residue, thickness of the bladder wall), Decreased rectal diameter, decreased urine output, ; Improved growth (weight gain), ; Improvement in quality of life (numbers of patients with improvement in quality of life, change in own‐perception of quality of life and change in the perception of improvement of the quality of life by relatives). INCLUSION CRITERIA: Children and adolescents aged 05 to 17 years with vesicoureteral dysfunction